<?xml version='1.0' encoding='utf-8'?>
<document id="30251061"><sentence text="Dose reduction, oral application, and order of intake to preserve aspirin antiplatelet effects in dipyrone co-medicated chronic artery disease patients."><entity charOffset="66-73" id="DDI-PubMed.30251061.s1.e0" text="aspirin" /><entity charOffset="98-106" id="DDI-PubMed.30251061.s1.e1" text="dipyrone" /><pair ddi="false" e1="DDI-PubMed.30251061.s1.e0" e2="DDI-PubMed.30251061.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30251061.s1.e0" e2="DDI-PubMed.30251061.s1.e1" /></sentence><sentence text="Dipyrone comedication in aspirin-treated patients is associated with impaired pharmacodynamic response to aspirin (high on-treatment platelet reactivity [HTPR])"><entity charOffset="0-8" id="DDI-PubMed.30251061.s2.e0" text="Dipyrone" /><entity charOffset="25-32" id="DDI-PubMed.30251061.s2.e1" text="aspirin" /><entity charOffset="106-113" id="DDI-PubMed.30251061.s2.e2" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.30251061.s2.e0" e2="DDI-PubMed.30251061.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30251061.s2.e0" e2="DDI-PubMed.30251061.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30251061.s2.e0" e2="DDI-PubMed.30251061.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30251061.s2.e1" e2="DDI-PubMed.30251061.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30251061.s2.e1" e2="DDI-PubMed.30251061.s2.e2" /></sentence><sentence text=" Additionally, in small observational studies, an association with impaired outcome has been described" /><sentence text=" In this uncontrolled, hypothesis-generating study, we aimed to investigate strategies to prevent this drug-drug interaction in patients with coronary artery disease (CAD)" /><sentence text="" /><sentence text="We analyzed pharmacodynamic response to aspirin in 80 dipyrone co-medicated CAD patients"><entity charOffset="40-47" id="DDI-PubMed.30251061.s6.e0" text="aspirin" /><entity charOffset="54-62" id="DDI-PubMed.30251061.s6.e1" text="dipyrone" /><pair ddi="false" e1="DDI-PubMed.30251061.s6.e0" e2="DDI-PubMed.30251061.s6.e0" /><pair ddi="false" e1="DDI-PubMed.30251061.s6.e0" e2="DDI-PubMed.30251061.s6.e1" /></sentence><sentence text=" Aspirin antiplatelet effects were measured using arachidonic acid (AA)-induced light-transmission aggregometry (LTA)"><entity charOffset="1-8" id="DDI-PubMed.30251061.s7.e0" text="Aspirin" /><entity charOffset="50-66" id="DDI-PubMed.30251061.s7.e1" text="arachidonic acid" /><pair ddi="false" e1="DDI-PubMed.30251061.s7.e0" e2="DDI-PubMed.30251061.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30251061.s7.e0" e2="DDI-PubMed.30251061.s7.e1" /></sentence><sentence text=" Platelet reactivity was associated with daily dose, administration form, and frequency" /><sentence text=" Additionally, we conducted a time-series analysis in patients with HTPR to aspirin with re-evaluation of pharmacodynamic response to aspirin after 5 days"><entity charOffset="76-83" id="DDI-PubMed.30251061.s9.e0" text="aspirin" /><entity charOffset="134-141" id="DDI-PubMed.30251061.s9.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.30251061.s9.e0" e2="DDI-PubMed.30251061.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30251061.s9.e0" e2="DDI-PubMed.30251061.s9.e1" /></sentence><sentence text="" /><sentence text="Patients' mean age was 75" /><sentence text="5 ± 9" /><sentence text="8 years" /><sentence text=" Forty-three (54%) were male, 22 (27" /><sentence text="5%) obese, and 38 (47" /><sentence text="5%) diabetics" /><sentence text=" Baseline characteristics, cardiovascular risk factors, comorbidities, comedication, or laboratory parameters did not differ between patients with or without HTPR" /><sentence text=" HTPR to aspirin occurred in 34 out of 80 patients (42"><entity charOffset="9-16" id="DDI-PubMed.30251061.s18.e0" text="aspirin" /></sentence><sentence text="5%)" /><sentence text=" The incidence of HTPR was associated with dipyrone daily dose (&lt; 1 g/day: HTPR 20% vs"><entity charOffset="43-51" id="DDI-PubMed.30251061.s20.e0" text="dipyrone" /></sentence><sentence text=" &gt; 3 g/day: HTPR 50%, p &gt; 0" /><sentence text="0001) and form of administration (i" /><sentence text="v" /><sentence text=" 87" /><sentence text="5% vs" /><sentence text=" oral 37" /><sentence text="5%; p &lt; 0" /><sentence text="0001)" /><sentence text=" A strict order of intake (aspirin 30 min prior to dipyrone) restored aspirin antiplatelet effects in all patients (HTPR before 100% vs"><entity charOffset="27-34" id="DDI-PubMed.30251061.s29.e0" text="aspirin" /><entity charOffset="51-59" id="DDI-PubMed.30251061.s29.e1" text="dipyrone" /><entity charOffset="70-77" id="DDI-PubMed.30251061.s29.e2" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.30251061.s29.e0" e2="DDI-PubMed.30251061.s29.e0" /><pair ddi="false" e1="DDI-PubMed.30251061.s29.e0" e2="DDI-PubMed.30251061.s29.e1" /><pair ddi="false" e1="DDI-PubMed.30251061.s29.e0" e2="DDI-PubMed.30251061.s29.e2" /><pair ddi="false" e1="DDI-PubMed.30251061.s29.e1" e2="DDI-PubMed.30251061.s29.e1" /><pair ddi="false" e1="DDI-PubMed.30251061.s29.e1" e2="DDI-PubMed.30251061.s29.e2" /></sentence><sentence text=" HTPR after 0%, p = 0" /><sentence text="0002)" /><sentence text="" /><sentence text="This study shows that dipyrone should be used with caution in aspirin-treated patients"><entity charOffset="22-30" id="DDI-PubMed.30251061.s33.e0" text="dipyrone" /><entity charOffset="62-69" id="DDI-PubMed.30251061.s33.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.30251061.s33.e0" e2="DDI-PubMed.30251061.s33.e0" /><pair ddi="false" e1="DDI-PubMed.30251061.s33.e0" e2="DDI-PubMed.30251061.s33.e1" /></sentence><sentence text=" If dipyrone seems indispensable, the lowest effective dose and a strict order of intake seem favorable"><entity charOffset="4-12" id="DDI-PubMed.30251061.s34.e0" text="dipyrone" /></sentence><sentence text="" /></document>